The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD

Ma'en Obeidat, Alen Faiz, Xuan Li, Maarten Van Den Berge, Nadia N. Hansel, Philippe Joubert, Ke Hao, Corry Anke Brandsma, Nicholas Rafaels, Rasika Mathias, Ingo Ruczinski, Terri H. Beaty, Kathleen C. Barnes, S. F. Paul Man, Peter D. Paré, Don D. Sin

Research output: Contribution to journalArticle

Abstract

Inhaled corticosteroids (ICS) are widely prescribed for patients with chronic obstructive pulmonary disease (COPD), yet have variable outcomes and adverse reactions, which may be genetically determined. The primary aim of the study was to identify the genetic determinants for forced expiratory volume in 1 s (FEV1) changes related to ICS therapy. In the Lung Health Study (LHS)-2, 1116 COPD patients were randomised to the ICS triamcinolone acetonide (n=559) or placebo (n=557) with spirometry performed every 6 months for 3 years. We performed a pharmacogenomic genome-wide association study for the genotype-by-ICS treatment effect on 3 years of FEV1 changes (estimated as slope) in 802 genotyped LHS-2 participants. Replication was performed in 199 COPD patients randomised to the ICS, fluticasone or placebo. A total of five loci showed genotype-by-ICS interaction at p<5×10−6; of these, single nucleotide polymorphism (SNP) rs111720447 on chromosome 7 was replicated (discovery p=4.8×10−6, replication p=5.9×10−5) with the same direction of interaction effect. ENCODE (Encyclopedia of DNA Elements) data revealed that in glucocorticoid-treated (dexamethasone) A549 alveolar cell line, glucocorticoid receptor binding sites were located near SNP rs111720447. In stratified analyses of LHS-2, genotype at SNP rs111720447 was significantly associated with rate of FEV1 decline in patients taking ICS (C allele β 56.36 mL·year−1, 95% CI 29.96-82.76 mL·year−1) and in patients who were assigned to placebo, although the relationship was weaker and in the opposite direction to that in the ICS group (C allele β −27.57 mL·year−1, 95% CI −53.27- −1.87 mL·year−1). The study uncovered genetic factors associated with FEV1 changes related to ICS in COPD patients, which may provide new insight on the potential biology of steroid responsiveness in COPD.

Original languageEnglish (US)
Article number1900521
JournalEuropean Respiratory Journal
Volume54
Issue number6
DOIs
StatePublished - Dec 1 2019

Fingerprint

Pharmacogenetics
Chronic Obstructive Pulmonary Disease
Adrenal Cortex Hormones
Lung
Forced Expiratory Volume
Single Nucleotide Polymorphism
Genotype
Placebos
Health
Alleles
Encyclopedias
Alveolar Epithelial Cells
Triamcinolone Acetonide
Chromosomes, Human, Pair 7
Genome-Wide Association Study
Spirometry
Glucocorticoid Receptors
Dexamethasone
Glucocorticoids
Steroids

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD. / Obeidat, Ma'en; Faiz, Alen; Li, Xuan; Van Den Berge, Maarten; Hansel, Nadia N.; Joubert, Philippe; Hao, Ke; Brandsma, Corry Anke; Rafaels, Nicholas; Mathias, Rasika; Ruczinski, Ingo; Beaty, Terri H.; Barnes, Kathleen C.; Paul Man, S. F.; Paré, Peter D.; Sin, Don D.

In: European Respiratory Journal, Vol. 54, No. 6, 1900521, 01.12.2019.

Research output: Contribution to journalArticle

Obeidat, M, Faiz, A, Li, X, Van Den Berge, M, Hansel, NN, Joubert, P, Hao, K, Brandsma, CA, Rafaels, N, Mathias, R, Ruczinski, I, Beaty, TH, Barnes, KC, Paul Man, SF, Paré, PD & Sin, DD 2019, 'The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD', European Respiratory Journal, vol. 54, no. 6, 1900521. https://doi.org/10.1183/13993003.00521-2019
Obeidat, Ma'en ; Faiz, Alen ; Li, Xuan ; Van Den Berge, Maarten ; Hansel, Nadia N. ; Joubert, Philippe ; Hao, Ke ; Brandsma, Corry Anke ; Rafaels, Nicholas ; Mathias, Rasika ; Ruczinski, Ingo ; Beaty, Terri H. ; Barnes, Kathleen C. ; Paul Man, S. F. ; Paré, Peter D. ; Sin, Don D. / The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD. In: European Respiratory Journal. 2019 ; Vol. 54, No. 6.
@article{a0b23fd028534dba9b926fca3dcf6677,
title = "The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD",
abstract = "Inhaled corticosteroids (ICS) are widely prescribed for patients with chronic obstructive pulmonary disease (COPD), yet have variable outcomes and adverse reactions, which may be genetically determined. The primary aim of the study was to identify the genetic determinants for forced expiratory volume in 1 s (FEV1) changes related to ICS therapy. In the Lung Health Study (LHS)-2, 1116 COPD patients were randomised to the ICS triamcinolone acetonide (n=559) or placebo (n=557) with spirometry performed every 6 months for 3 years. We performed a pharmacogenomic genome-wide association study for the genotype-by-ICS treatment effect on 3 years of FEV1 changes (estimated as slope) in 802 genotyped LHS-2 participants. Replication was performed in 199 COPD patients randomised to the ICS, fluticasone or placebo. A total of five loci showed genotype-by-ICS interaction at p<5×10−6; of these, single nucleotide polymorphism (SNP) rs111720447 on chromosome 7 was replicated (discovery p=4.8×10−6, replication p=5.9×10−5) with the same direction of interaction effect. ENCODE (Encyclopedia of DNA Elements) data revealed that in glucocorticoid-treated (dexamethasone) A549 alveolar cell line, glucocorticoid receptor binding sites were located near SNP rs111720447. In stratified analyses of LHS-2, genotype at SNP rs111720447 was significantly associated with rate of FEV1 decline in patients taking ICS (C allele β 56.36 mL·year−1, 95{\%} CI 29.96-82.76 mL·year−1) and in patients who were assigned to placebo, although the relationship was weaker and in the opposite direction to that in the ICS group (C allele β −27.57 mL·year−1, 95{\%} CI −53.27- −1.87 mL·year−1). The study uncovered genetic factors associated with FEV1 changes related to ICS in COPD patients, which may provide new insight on the potential biology of steroid responsiveness in COPD.",
author = "Ma'en Obeidat and Alen Faiz and Xuan Li and {Van Den Berge}, Maarten and Hansel, {Nadia N.} and Philippe Joubert and Ke Hao and Brandsma, {Corry Anke} and Nicholas Rafaels and Rasika Mathias and Ingo Ruczinski and Beaty, {Terri H.} and Barnes, {Kathleen C.} and {Paul Man}, {S. F.} and Par{\'e}, {Peter D.} and Sin, {Don D.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1183/13993003.00521-2019",
language = "English (US)",
volume = "54",
journal = "European Respiratory Journal, Supplement",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "6",

}

TY - JOUR

T1 - The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD

AU - Obeidat, Ma'en

AU - Faiz, Alen

AU - Li, Xuan

AU - Van Den Berge, Maarten

AU - Hansel, Nadia N.

AU - Joubert, Philippe

AU - Hao, Ke

AU - Brandsma, Corry Anke

AU - Rafaels, Nicholas

AU - Mathias, Rasika

AU - Ruczinski, Ingo

AU - Beaty, Terri H.

AU - Barnes, Kathleen C.

AU - Paul Man, S. F.

AU - Paré, Peter D.

AU - Sin, Don D.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Inhaled corticosteroids (ICS) are widely prescribed for patients with chronic obstructive pulmonary disease (COPD), yet have variable outcomes and adverse reactions, which may be genetically determined. The primary aim of the study was to identify the genetic determinants for forced expiratory volume in 1 s (FEV1) changes related to ICS therapy. In the Lung Health Study (LHS)-2, 1116 COPD patients were randomised to the ICS triamcinolone acetonide (n=559) or placebo (n=557) with spirometry performed every 6 months for 3 years. We performed a pharmacogenomic genome-wide association study for the genotype-by-ICS treatment effect on 3 years of FEV1 changes (estimated as slope) in 802 genotyped LHS-2 participants. Replication was performed in 199 COPD patients randomised to the ICS, fluticasone or placebo. A total of five loci showed genotype-by-ICS interaction at p<5×10−6; of these, single nucleotide polymorphism (SNP) rs111720447 on chromosome 7 was replicated (discovery p=4.8×10−6, replication p=5.9×10−5) with the same direction of interaction effect. ENCODE (Encyclopedia of DNA Elements) data revealed that in glucocorticoid-treated (dexamethasone) A549 alveolar cell line, glucocorticoid receptor binding sites were located near SNP rs111720447. In stratified analyses of LHS-2, genotype at SNP rs111720447 was significantly associated with rate of FEV1 decline in patients taking ICS (C allele β 56.36 mL·year−1, 95% CI 29.96-82.76 mL·year−1) and in patients who were assigned to placebo, although the relationship was weaker and in the opposite direction to that in the ICS group (C allele β −27.57 mL·year−1, 95% CI −53.27- −1.87 mL·year−1). The study uncovered genetic factors associated with FEV1 changes related to ICS in COPD patients, which may provide new insight on the potential biology of steroid responsiveness in COPD.

AB - Inhaled corticosteroids (ICS) are widely prescribed for patients with chronic obstructive pulmonary disease (COPD), yet have variable outcomes and adverse reactions, which may be genetically determined. The primary aim of the study was to identify the genetic determinants for forced expiratory volume in 1 s (FEV1) changes related to ICS therapy. In the Lung Health Study (LHS)-2, 1116 COPD patients were randomised to the ICS triamcinolone acetonide (n=559) or placebo (n=557) with spirometry performed every 6 months for 3 years. We performed a pharmacogenomic genome-wide association study for the genotype-by-ICS treatment effect on 3 years of FEV1 changes (estimated as slope) in 802 genotyped LHS-2 participants. Replication was performed in 199 COPD patients randomised to the ICS, fluticasone or placebo. A total of five loci showed genotype-by-ICS interaction at p<5×10−6; of these, single nucleotide polymorphism (SNP) rs111720447 on chromosome 7 was replicated (discovery p=4.8×10−6, replication p=5.9×10−5) with the same direction of interaction effect. ENCODE (Encyclopedia of DNA Elements) data revealed that in glucocorticoid-treated (dexamethasone) A549 alveolar cell line, glucocorticoid receptor binding sites were located near SNP rs111720447. In stratified analyses of LHS-2, genotype at SNP rs111720447 was significantly associated with rate of FEV1 decline in patients taking ICS (C allele β 56.36 mL·year−1, 95% CI 29.96-82.76 mL·year−1) and in patients who were assigned to placebo, although the relationship was weaker and in the opposite direction to that in the ICS group (C allele β −27.57 mL·year−1, 95% CI −53.27- −1.87 mL·year−1). The study uncovered genetic factors associated with FEV1 changes related to ICS in COPD patients, which may provide new insight on the potential biology of steroid responsiveness in COPD.

UR - http://www.scopus.com/inward/record.url?scp=85075956883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075956883&partnerID=8YFLogxK

U2 - 10.1183/13993003.00521-2019

DO - 10.1183/13993003.00521-2019

M3 - Article

C2 - 31537701

AN - SCOPUS:85075956883

VL - 54

JO - European Respiratory Journal, Supplement

JF - European Respiratory Journal, Supplement

SN - 0903-1936

IS - 6

M1 - 1900521

ER -